Larimar Therapeutics Inc (LRMR)

Currency in USD
3.460
-0.050(-1.43%)
Real-time Data·
LRMR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.3853.610
52 wk Range
1.6105.370
Key Statistics
Prev. Close
3.51
Open
3.51
Day's Range
3.385-3.61
52 wk Range
1.61-5.37
Volume
510.42K
Average Volume (3m)
1.38M
1-Year Change
-2.5352%
Book Value / Share
1.62
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LRMR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
14.667
Upside
+323.89%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Larimar Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Larimar Therapeutics Inc Company Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Larimar Therapeutics Inc SWOT Analysis


Nomlabofusp Promise
Larimar's lead drug candidate shows potential to address the root cause of Friedreich's ataxia, positioning the company at the forefront of FA treatment research
Clinical Milestones
Explore Larimar's progress in adult and pediatric trials, with key data releases expected to serve as potential catalysts for stock performance
Regulatory Landscape
Learn about Larimar's strategy for accelerated approval and how potential FDA easements for rare diseases could impact the company's timeline
Market Dynamics
Delve into Larimar's positioning in the evolving FA treatment market, with analyst price targets ranging from $10 to $40 despite recent stock volatility
Read full SWOT analysis

Compare LRMR to Peers and Sector

Metrics to compare
LRMR
Peers
Sector
Relationship
P/E Ratio
−2.2x−4.8x−0.6x
PEG Ratio
0.03−0.050.00
Price/Book
2.1x4.4x2.6x
Price / LTM Sales
-172.4x3.3x
Upside (Analyst Target)
239.0%49.1%44.6%
Fair Value Upside
Unlock−19.8%6.0%Unlock

Analyst Ratings

10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 14.667
(+323.89% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Leerink Partners
Buy12.00+247.32%-New CoverageJan 05, 2026
Citizens
Buy18.00+420.98%-MaintainOct 06, 2025
Citizens
Buy18.00+420.98%-MaintainOct 03, 2025
Oppenheimer
Buy21.00+507.81%26.00MaintainOct 02, 2025
Baird
Buy7.00+102.60%10.00MaintainSep 30, 2025

Earnings

Latest Release
Nov 05, 2025
EPS / Forecast
-0.61 / -0.4128
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

LRMR Income Statement

People Also Watch

2.05
NMRA
+3.46%
15.48
LENZ
-5.03%
4.86
IRWD
-1.72%
18.91
DYN
+0.80%
9.51
FDMT
+3.93%

FAQ

What Is the Larimar Therapeutics Inc (LRMR) Stock Price Today?

The Larimar Therapeutics Inc stock price today is 3.460

What Stock Exchange Does Larimar Therapeutics Inc Trade On?

Larimar Therapeutics Inc is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Larimar Therapeutics Inc?

The stock symbol for Larimar Therapeutics Inc is "LRMR."

What Is the Larimar Therapeutics Inc Market Cap?

As of today, Larimar Therapeutics Inc market cap is 295.29M.

What Is Larimar Therapeutics Inc's Earnings Per Share (TTM)?

The Larimar Therapeutics Inc EPS (TTM) is -1.95.

When Is the Next Larimar Therapeutics Inc Earnings Date?

Larimar Therapeutics Inc will release its next earnings report on Mar 18, 2026.

From a Technical Analysis Perspective, Is LRMR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Larimar Therapeutics Inc Stock Split?

Larimar Therapeutics Inc has split 1 times.

How Many Employees Does Larimar Therapeutics Inc Have?

Larimar Therapeutics Inc has 65 employees.

What is the current trading status of Larimar Therapeutics Inc (LRMR)?

As of Feb 04, 2026, Larimar Therapeutics Inc (LRMR) is trading at a price of 3.460, with a previous close of 3.510. The stock has fluctuated within a day range of 3.385 to 3.610, while its 52-week range spans from 1.610 to 5.370.

What Is Larimar Therapeutics Inc (LRMR) Price Target According to Analysts?

The average 12-month price target for Larimar Therapeutics Inc is USD14.667, with a high estimate of USD26 and a low estimate of USD7. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +323.89% Upside potential.

What Is the LRMR After Hours Price?

LRMR's last after hours stock price is 3.511, the stock has decreased by 0.001, or 0.030%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.